Eculizumab (anti-Complement C5) - Primary antibody, specific to C5, >95%, Human IgG2+Human IgG4, INHIBITOR of Complement C5 inhibitor, INHIBITOR of Complement C5 inhibitor
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2+Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated













